To evaluate the outcomes of unrelated bone marrow transplantation facilitated by TCTMDR, we focused on 48 marrow transplants performed in Taiwan during the period May 1994 to June 1997. Follow-up of these 48 cases was made up to 30 May 1998. The average length of follow-up was 328 days (range 7-1385 days). All the donor/recipient pairs were HLA-A, B and DR matched and were divided into two risk groups based on diagnosis and stage of disease. There were 24 standard risk and 24 high risk patients. Engraftment occurred in 40 patients (83.3%). Acute and chronic GVHD was observed in 80% of evaluable patients and accounts for 41% of deaths. The second leading cause of death was infection, accounting for 35% of deaths. The overall probability of survival for the 48 patients after BMT over 2 years was 33.3% (95% CI 19.67-46.32%). The probability of survival for standard risk and high risk groups was 54% and 8%, respectively. In multivariate analysis, patients who were younger, in the standard risk group, or with a shorter search interval showed a higher survival probability.
Bone marrow transplantation has been accepted as potentially curative for a wide variety of hematologic neoplasms, bone marrow failure syndromes and certain congenital diseases. [1] [2] [3] [4] The first bone marrow transplant in Taiwan was carried out in 1983. 5 Since then, increasing numbers of patients with hematological disorders have undergone allogeneic marrow transplantation. However, more than twothirds of patients were unable to find a matched sibling. In order to increase the probability of providing matched donors for patients, the Tzu Chi Taiwan Marrow donor Registry (TCTMDR) was established in October 1993 to recruit HLA-type volunteers who would donate bone marrow to unrelated recipients. 6 In this report we present the results of 48 marrow transplants performed in Taiwan
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Materials and methods

The TCTMDR
The TCTMDR was established in October 1993 by the Buddhist Tzu Chi Foundation to facilitate donor search and marrow procurement for patients who need unrelated HLA matched donors. By the end of June 1998, more than 165 000 volunteers had been recruited (100% serologically typed for HLA-A and B, 25% DNA-typed for HLA-DR and DQ). The first request for an unrelated donor search was received in November 1993. To date, more than 4146 searches have been performed (668 from Taiwan, 3478 from 23 foreign countries). For domestic patients, the rate of identifying an HLA-A, B and DR matched donor is 60%. However, for patients from foreign countries, the rate is only 6%.
Patients
The first unrelated bone marrow transplant provided by the TCTMDR was carried out in May 1994 for a patient with acute myelogenous leukemia (AML). Between May 1994 and June 1998, 88 unrelated donors were provided for transplants, of which 62 BMT procedures were carried out in Taiwan. Fourteen patients who receive BMTs later than June 1997 were excluded from this report because of the short follow-up period. They were divided into two groups: acute leukemia and lymphoma in first complete remission, chronic myelogenous leukemia in first chronic phase, severe aplastic anemia, thalassemia major and ChediakHigashi syndrome are considered to be standard risk groups. Leukemia beyond first complete remission or beyond chronic phase, and advanced myelodysplastic syndrome are included in the high risk groups.
Patients received a variety of preconditioning regimens determined by the individual transplantation centers. Most patients with leukemia received total body irradiation along with chemotherapy. Methods for prophylaxis graft-versushost disease (GVHD) varied from center to center. Methotrexate, cyclosporin A and steroids were used most often.
No patient received T cell-depleted marrow. Regimens for AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; SAA = severe aplastic anemia; C-H syndrome = Chediak-Higashi syndrome.
Table 2
Characteristics of donors and recipients prophylaxis of infection in the post-transplant period included ganciclovir, acyclovir, trimethoprim/sulfamethoxazole and other antibiotics, depending on individual protocols.
Characteristic
Data collection
Transplants were performed at seven centers in Taiwan as listed in the Appendix. The average length of follow-up was 328 days (range 7-1385 days). Data on survival were gathered up to 31 May 1998. The day of engraftment was defined as the first of 3 consecutive days on which the neutrophil count exceeded 500 per cubic millimeter. Engraftment failure There were five patients with acute GVHD followed by chronic GVHD and one patient with chronic GVHD. The overall incidence of GVHD was approximately 80% (32/40).
was defined as no evidence of myeloid recovery (ANC Ͻ 0.5 × 10 9 /l) at day 35 post-BMT. Those who died within 35 days and with no evidence of hematopoietic recovery were classified as uncertain engraftment. Diagnoses of acute and chronic GVHD were based on clinical and histological evidence and classified according to criteria previously established.
7,8
Statistical analysis
Statistical analyses were performed using SAS software (Cary, NC, USA). Kaplan-Meier estimates were used to display survival between different patient groups. Log-rank tests were used for univariate analysis. Proportional-hazard models were employed for determining the relative importance of factors in predicting survival after transplantation. The following independent variables were considered in the model: recipient age, recipient cytomegalovirus (CMV) and hepatitis B virus (HBV) status, interval between initial search to transplantation, and risk groups based on diagnosis and disease stage. Only the variables where coefficients had P values less than 0.05 are reported. Tables 1  and 2 . All donor/recipient pairs were HLA-A, B serologically matched and HLA-DR matched at DNA low-resolution level. The average number of days required for the search and coordination process in 48 cases was 278 (range 32-1132). There were 24 standard risk and 24 high-risk patients. Twenty-six out of 48 patients were younger than 20 years of age, and 22 recipients were over 20 years. Engraftment occurred in 40 patients (83.3%), two had graft failure (4.2%), and six had uncertain engraftment (12.5%).
Results
Characteristics of patients and donors are shown in
GVHD
Incidence of acute and chronic GVHD is shown in Table 3 . Thirty-one patients had acute GVHD and six had chronic GVHD (five preceded by acute GVHD, one chronic GVHD only). After excluding cases of graft failure and uncertain take, the overall incidence of GVHD was 80%. Acute GVHD was observed in 31 (77.5%) of patients, of whom 15 (37.5%) had grade III, IV and 16 (40%) grade I, II. Chronic GVHD was observed in six (15%) patients.
Post-transplant infection
Clinically obvious infection was found in 31 (64.6%) patients in the post-transplant period. Among them, evidence of CMV infection was present in nine (18.8%) patients, CMV pneumonitis in four patients, and CMV retinitis in one patient. There were two fungal infections. The other 20 infections were caused by bacteria or were clinically sepsis with no definite pathogen. Ten (20.8%) patients developed interstitial pneumonitis; four (8.3%) were due to CMV pneumonitis, and the other six (12.5%) were thought to be due to idiopathic interstitial pneumonitis.
Survival and relapse
As shown in Figure 1 , disease free-survival at 2 years for standard risk patients was 54% (95% CI 34-74%, n = 24) and for high risk patients 8% (95% CI 0-19%, n = 24). The probability of disease-free survival for patients with acute leukemia in the standard risk group was 50% (95% CI 10-89%, n = 6), and 9% (95% CI 0-25%, n = 11) for patients in the high-risk group. Disease-free survival for patients with chronic myelogenous leukemia in the standard risk group was 50% (95% CI 16-84%, n = 8) and in the high risk group 11% (95% CI 0-32%, n = 9). All patients transplanted for thalassemia major, and Chediak-Higashi syndrome survived, but only two of the six cases with severe aplastic anemia did so. It was also noted that recipients under the age of 20 in the standard risk group had the best probability (56%) of survival within the 2 years. Of the 40 who engrafted, eight (20%) patients suffered from recurrence of their primary disease. Primary and secondary causes of death are listed in Table 4 . GVHD (41.2%), infection (35.2%) and interstitial pneumonitis (23.6%) accounted for most of the deaths.
Factors examined by multivariable analysis significantly affecting survival rate are presented in Table 5 . Patients who were younger, in the standard risk group or with a shorter search interval before transplantation had better survival rates.
Discussion
Although the TCTMDR has only been established for 5 years, it has shown that cooperation between medical insti- In our study, engraftment occurred successfully in 83.3% of recipients in accordance with the previous report from the NMDP (86.5%). 4 However, the overall incidence of acute and chronic GVHD is as high as 80%, and accounts for 41% of deaths. The probability of grade II, III or IV acute GVHD is 67% in compliance with the previous report from the NMDP (64%). 4 Chen et al 9 reported that a low incidence of acute GVHD was found in patients with hematologic malignancies and severe aplastic anemia (14.3% and 6.5%, respectively) using HLA-matched siblings in Taiwan. The discrepancy may be attributed to HLA polymorphisms between recipients and unrelated donors that are not detectable by serotyping for HLA-A, B and low resolution typing for HLA-DR.
The overall disease-free survival of UBMT facilitated by the TCTMDR in Taiwan was 33.3% (95% CI 19.7-46.3%). Patients aged under 20 with standard risk disease had the highest probability (56%) of disease-free survival over 2 years. However, results of UBMT in the high risk group are disappointing. They compared very poorly with reports from other countries. 4, 10, 11 Three characteristics were found to be associated with better survival: younger age, in the standard risk group, and with shorter search and coordination interval before transplantation. These results indicate that selection of patients and prompt search processing is of vital importance to improve BMT success.
A long search time is of major concern for advanced stage patients who may relapse before having the opportunity of receiving a BMT. The interval from initial search for matched donors to actual transplant in patients from the US National Marrow Donor Program (NMDP), 12 Canadian Unrelated Bone Marrow Donor Registry (UBMDR), 13 Italian Bone Marrow Transplant Group (GITMO), 14 and Japan Marrow Donor Program (JMDP) 15 was 208 days (median), 210 days (mean), 8 months and 1 year, respectively. In our study, the average number of days for the search and coordination process was 278 (range 32-1132) days. With multivariate analysis it was found that donor search time affects patient survival. These findings are in agreement with other studies which demonstrated that duration of disease before transplantation was a predictor of survival. 11, 16 With more registered voluntary donors, a higher percentage of HLA-DR types in our data bank, and better international cooperation for searches, we hope that the search interval will be reduced.
Several actions have been taken to improve UBMT outcomes. First, HLA-typing for patients and potential donors is performed in one central immunogenetic center using molecular testing for both HLA class I and II. This will assure better matches between recipients and donors. Second, criteria for UBMT were reviewed with careful patient collection. Finally, improved prophylaxis for GVHD and infection control are recommended. We hope that these measures will improve the accuracy of matching, decrease the incidence of GVHD and infection, and prolong patient survival after bone marrow transplantation from unrelated donors in Taiwan.
